Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study)

Table 3 Survival and Progression^a

		months (median)		95 % CI		p-value
Follow-up		16.14
Overall survival
	from first diagnosis	127.9		87.1- 168.7
	from first diagnosis liver metastases	56.3		44.5 - 67.9
	from first interventional treatment	21.9		11.1 - 32.6
Maximum diameter of liver metastases (≥ vs. < 3.9 cm)		16.1	38.7	9.8 - 22.5	19.6 - 57.8	0.001
Best response overall (OR, RECIST)
	OR (CR + PR) (n = 37) vs. PD + SD (n = 22)	36.6	10.2	26.4 - 46.7	6.1 - 14.3	< 0.001
Disease controlled during follow-up (yes/no)^b		38.5	14.2	27.1 - 39.7	9.4 - 18.9	0.002

Survival (from first diagnosis, first diagnosis of liver metastases, first interventional treatment of LMBC) estimated according to the Kaplan-Meier method. Factors found to have an independent impact on survival in the multivariate model (Table 5) were used as stratifying variables in a Kaplan-Meier analysis of survival after first interventional LMBC treatment. The log rank test was used for survival comparison
^aAddressing overall survival data and significant influencing factors from multivariate cox regression
^bPatients demonstrating either overall objective response, stable disease, or limited disease progression amenable to repeat local ablation were regarded as having controlled disease. Disease progression not amenable to local intervention was defined as non-controlled

ISSN: 1471-2407